Horizon Therapeutics Public (NASDAQ:HZNP) Receives New Coverage from Analysts at StockNews.com

Posted by on Jun 14th, 2023

Research analysts at StockNews.com started coverage on shares of Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) in a research note issued to investors on Wednesday. The firm set a “buy” rating on the biopharmaceutical company’s stock.

Separately, TheStreet cut Horizon Therapeutics Public from a “b-” rating to a “c+” rating in a report on Monday, May 8th. Eight research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Horizon Therapeutics Public has an average rating of “Hold” and an average target price of $111.42.

Horizon Therapeutics Public Trading Up 0.2 %

Shares of Horizon Therapeutics Public stock opened at $100.06 on Wednesday. Horizon Therapeutics Public has a fifty-two week low of $57.84 and a fifty-two week high of $113.83. The firm has a market cap of $22.88 billion, a PE ratio of 62.93, a P/E/G ratio of 2.95 and a beta of 1.12. The business’s fifty day moving average is $106.15 and its two-hundred day moving average is $108.17. The company has a quick ratio of 3.89, a current ratio of 4.07 and a debt-to-equity ratio of 0.50.

Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) last issued its earnings results on Wednesday, May 3rd. The biopharmaceutical company reported $0.83 earnings per share for the quarter, missing analysts’ consensus estimates of $1.17 by ($0.34). Horizon Therapeutics Public had a net margin of 10.40% and a return on equity of 20.31%. The firm had revenue of $832.10 million during the quarter, compared to analyst estimates of $897.06 million. During the same quarter in the previous year, the business posted $1.34 EPS. Horizon Therapeutics Public’s revenue was down 6.0% compared to the same quarter last year. Analysts anticipate that Horizon Therapeutics Public will post 4.81 earnings per share for the current year.

Institutional Trading of Horizon Therapeutics Public

A number of hedge funds and other institutional investors have recently modified their holdings of HZNP. Elequin Securities LLC purchased a new stake in shares of Horizon Therapeutics Public during the fourth quarter worth about $25,000. TFC Financial Management Inc. acquired a new stake in Horizon Therapeutics Public in the first quarter worth approximately $25,000. Whittier Trust Co. of Nevada Inc. acquired a new stake in Horizon Therapeutics Public in the fourth quarter worth approximately $28,000. CoreCap Advisors LLC acquired a new stake in Horizon Therapeutics Public in the fourth quarter worth approximately $30,000. Finally, Ameritas Advisory Services LLC acquired a new stake in Horizon Therapeutics Public in the first quarter worth approximately $31,000. 91.01% of the stock is owned by hedge funds and other institutional investors.

About Horizon Therapeutics Public

(Get Rating)

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS.

Read More

Analyst Recommendations for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.